NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6658.00 42.00 (0.63%)

Near 52W High of ₹6862.50

547.0K NSE+BSE Volume

NSE 27 Jun, 2025 3:31 PM (IST)

176,749

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Dividend

Divi's Laboratories Ltd. has an upcoming dividend of ₹30.00 per share due on 25 Jul 2025 See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

19 May 2025

6658.00

0.63%

Divi's Laboratories (DIVI IN) Q4FY25 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY25 EBITDA beat our estimates led by higher gross margin (62%; up 200 bps QoQ). We expect GMs to sustain, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates broadly remain unchanged. We expect 22% EBITDA CAGR and 15% PAT CAGR over FY25-27E. At CMP, stock is trading at...

Divi's Laboratories Ltd. has gained 47.22% in the last 1 Year

Divi's Laboratories Ltd.

25 Mar 2025

6658.00

0.63%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

05 Feb 2025

6658.00

0.63%

High value projects will sustain growth in Custom Synthesis segment

Accumulate: Divi's Laboratories Ltd.

Target

KRChoksey

DIVISLAB revenue beat our estimates (+3.9%) due to strong growth in Custom Synthesis segment. EBITDA beat our estimates due to better-than-expected gross profit and lower than expected employee expenses. Adj. PAT was beat due to lower-than-expected effective tax rate.

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

04 Feb 2025

6658.00

0.63%

DIVI'S LABORATORIES

Accumulate: Divi's Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Divi's Laboratories .. has an average target of 5900.88 from 8 brokers.

Divi's Laboratories Ltd.

03 Feb 2025

6658.00

0.63%

Custom synthesis drives earnings; generics stable QoQ

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered in-line revenue. However, it reported better-than-expected EBITDA/PAT led by a better product mix and lower tax rate (due to the shift to a new tax regime).

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

03 Feb 2025

6658.00

0.63%

Divis Labs (HOLD): Back to higher growth trajectory

Hold: Divi's Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q3 sales/EBITDA/PAT were 0.6%/7.5%/22.3% above our estimates. PAT was higher than estimated due to the adoption of the new tax regime

Divi's Laboratories .. has an average target of 5900.88 from 8 brokers.

Divi's Laboratories Ltd.

11 Nov 2024

6658.00

0.63%

Multiple growth levers to drive Custom Synthesis segment

Accumulate: Divi's Laboratories Ltd.

Target

KRChoksey

Divis Lab revenue beat our estimates significantly due to strong growth in the Custom Synthesis segment. EBITDA beat our estimate due to lower-than-expected other expenses and employee expenses.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

11 Nov 2024

6658.00

0.63%

Company set for continued growth

Buy: Divi's Laboratories Ltd.

Recommendation Target

Sharekhan

Divis Labs’ revenue for the quarter amounted to Rs. 2,238 crore, marking a 17% y-o-y increase and a 6% q-o-q rise, which was 4% above estimates.

Divi's Laboratories .. has an average target of 5900.88 from 8 brokers.

Divi's Laboratories Ltd.

10 Nov 2024

6658.00

0.63%

Divi's Labs (SELL): Healthy Q2; rich valuations

Sell: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

DIVI reported healthy 2QFY25 earnings which was a beat on our estimates. Exports contributed 87% of sales and the US 71%

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

07 Aug 2024

6658.00

0.63%

Ramp up in custom synthesis and new generic APIs to drive margins

Hold: Divi's Laboratories Ltd.

Target

KRChoksey

DIVISLAB continues to post results below estimates due to continued weakness in generic pricing. We hence cut down our EPS estimates by 3% each for FY25E/FY26E.

Divi's Laboratories Ltd. has gained 47.22% in the last 1 Year

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf